46O - Introduction and presentation of: A Phase 1a/2a trial of AVID100, an anti-EGFR antibody-drug conjugate

Date 07 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session ADC payloads
Topics Cytotoxic agents
Presenter Anthony Tolcher
Citation Annals of Oncology (2018) 29 (suppl_3): iii7-iii9. 10.1093/annonc/mdy048
Authors A. Tolcher1, K. Papadopoulos1, Y. Cole2, K. Rivas3, S. Chandana4, S. Sinclair5, D. Wood5, P.I. Nadler5, N. Lakhani6
  • 1Director Of Clinical Research, South Texas Accelerated Research Therapeutics (START), 78229 - San Antonio/US
  • 2Research Nurse, START Midwest, 78229 - Grand Rapids/US
  • 3Research Nurse, South Texas Accelerated Research Therapeutics (START), 78229 - San Antonio/US
  • 4Investigator, START Midwest, 78229 - Grand Rapids/US
  • 5Medical Research, Formation Biologics, 78701 - Austin/US
  • 6Director Of Clinical Research, START Midwest, 78229 - Grand Rapids/US

Abstract

AVID100, an anti-EGFR-DM1 conjugate, showed potent activity in preclinical models in vitro and in vivo including in cell lines resistant to approved anti-EGFR mAbs.